Cancer Australia has established the Priority-driven Collaborative Cancer Research Scheme to support research that reduces the impact of cancer on the community and improves outcomes for people affected by cancer.
Update on 2024 PdCCRS
Cancer Australia is pausing the Priority-driven Collaborative Cancer Research Scheme (PdCCRS) for 2024 – there will not be a grant round this year. This decision was taken in response to a comprehensive review of Cancer Australia’s grants programs including the PdCCRS completed in 2023.
The review identified an opportunity for Cancer Australia to redesign the PdCCRS to ensure Cancer Australia’s research investment reflects the changed research landscape and is adapted to align with the goals of the Australian Cancer Plan.
Cancer Australia would like to thank all past and current PdCCRS grant recipients, Funding Partners, and the research community for their continued support of Cancer Australia’s grants programs. Cancer Australia will be conducting further consultation with stakeholders across the cancer research sector to inform the redesign of our research program.
Overview
The Priority-driven Collaborative Cancer Research Scheme is an innovative annual national research project grants funding scheme which brings together government and other funders to collaboratively fund cancer research in Australia.
This funding scheme helps to:
- coordinate funding of priority-driven cancer research at the national level,
- foster collaboration between cancer researchers to build Australia’s cancer research capacity, and
- foster consumer participation in cancer research, from design to implementation.
Working with the National Health and Medical Research Council (NHMRC)
This research scheme is managed by Cancer Australia and the agency collaborates with NHMRC in this grant scheme. NHMRC facilitates registration and initial assessment of applications, and endorses grants funded through this scheme in recognition of their scientific merit.
Successful Applicants in the 2023 Round
The Australian Government has awarded successful applicants in the 2023 round of the Priority-driven Collaborative Cancer Research Scheme, proudly supported by Cancer Australia, Australian Lions Childhood Cancer Research Foundation, Bowel Cancer Australia, Can Too Foundation, Leukaemia Foundation, Lung Foundation Australia, My Room Children’s Cancer Charity Limited, Ovarian Cancer Research Foundation and The Kids’ Cancer Project.
Successful grants in the 2023 PdCCRS round are as follows:
Boyle, Sarah
Centre for Cancer Biology (University of South Australia and SA Pathology)
Tackling breast cancer growth and metastasis by suppressing ROCK-regulated paracrine signalling.
Funded by: Cancer Australia, Can Too Foundation
Byrne, Hilary
University of Sydney
How are you breathing today?
Funded by: Cancer Australia, Lung Foundation Australia
Cole, Alexander
Centenary Institute
Treating chemoresistant ovarian cancer: Blocking follistatin signalling to enhance the effects of chemotherapy and prevent recurrence of chemoresistant disease.
Funded by: Cancer Australia, Ovarian Cancer Research Foundation
D'Andrea, Richard
University of South Australia
Integrating cancer germline genetics, precision medicine and oncology to optimise management of paediatric AML.
Funded by: Cancer Australia, My Room Children’s Cancer Charity Limited, The Kids’ Cancer Project
Dun, Matt
The University of Newcastle
Taming free radicals to silence the epigenome of kinase active paediatric cancers.
Funded by: Cancer Australia, The Kids’ Cancer Project
Hindley, Nicholas
University of Sydney
From relativity to respiration: How ideas from Einstein’s general theory enable adaptative radiation therapy for lung cancer patients.
Funded by: Cancer Australia, Lung Foundation Australia
McDonald, Michelle
University of Sydney
The Skeleton: A Reservoir for Metastatic Outgrowth.
Funded by: Cancer Australia
Park, Susanna
University of Sydney
Harnessing metabolic, genetic and protein biomarkers to predict neurotoxicity in taxane-treated cancer patients (NeuroTax): A prospective validation cohort study
Funded by: Cancer Australia
Samuel, Michael
University of South Australia
Insights from the functional tumour secretome: new opportunities to monitor and halt colorectal cancer progression.
Funded by: Bowel Cancer Australia
Sanij, Elaine
St Vincent's Institute of Medical Research
Harnessing the nucleolar stress response in cancer therapy.
Funded by: Cancer Australia
Schumacher, Oliver
Edith Cowan University
Exercise as a novel therapeutic approach for sensitising prostate cancer to radiotherapy.
Funded by: Cancer Australia, Can Too Foundation
Selth, Luke
Flinders University
A novel hormonal therapy to treat lethal prostate cancer.
Funded by: Cancer Australia
Sutherland, Kate
The Walter and Eliza Hall Institute of Medical Research
Exploiting cell-of-origin features to improve treatment for KEAP1-mutant lung cancer.
Funded by: Cancer Australia
Tavakoli Shirazi, Paniz
The Council of the Queensland Institute of Medical Research
Effect of co-occurring mutations on therapy response and resistance.
Funded by: Cancer Australia
Thurgood, Lauren
Flinders University
Non-canonical PI3K targeting - novel therapies to exploit the lipid dependency of CLL.
Funded by: Leukaemia Foundation
Vandyke, Kate
The University of Adelaide
Priming the blood-brain barrier to improve drug delivery and treatment outcomes in diffuse midline glioma.
Funded by: Cancer Australia, Australian Lions Childhood Cancer Research Foundation, The Kids’ Cancer Project
Ziegler, David
University of New South Wales
Unlocking the potential of the blood-brain barrier in the fight against paediatric brain gliomas
Funded by: Cancer Australia
Cancer Australia's funding partners and the successful applicants in the PdCCRS rounds of:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007